Additional Insights to Mechanism of Action for NEM® Published

MRI-Feb-CoverESM Technologies, the manufacturer of leading eggshell membrane ingredient, NEM® has additional research published to explain how NEM® brand eggshell membrane supports healthy  joints.

NEM® brand eggshell membrane has been shown previously to reduce pro-inflammatory cytokines in-vitro in mitogen-challenged, healthy human immune cells — and now this mechanism of action has been extended to in-vivo studies as well.  The results from these studies, recently published in Modern Research in Inflammation, showed substantial reductions of a variety of pro-inflammatory cytokines while, importantly, having little effect on the anti-inflammatory cytokines evaluated.  The initial studies in healthy rats demonstrated large reductions (up to 88%) in cytokines that occur later in the inflammatory cascade (e.g. MCP-1, MIP-1β, RANTES, VEGF).  Whereas a follow-up study in inflammatory-challenged rats demonstrated significant reductions (40-44%) in IL-1β, a key primary mediator of inflammation.

Kevin J. Ruff, Ph.D., MBA, CCRP – Director of Scientific & Regulatory Affairs for ESM Technologies stated, “We were pleased to find evidence that NEM® helps to maintain a normal inflammatory response in healthy animals.  And the novel nature of this finding formed the basis for a patent (U.S. 8,580,315) that was recently granted for this same indication.”  Taken together, these studies establish that oral supplementation with NEM® can influence quite a number of cytokines associated with the progression of cartilage destruction within joints, providing a plausible basis for the mechanism of action of NEM® in-vivo; and this serves as an important step in explaining its observed clinical efficacy seen in multiple human studies.

These additional published studies show further substantiation for NEM® supporting a healthy inflammatory response.  The paper has published online Modern Research in Inflammation with available open access at


NEM® brand eggshell membrane is a novel dietary supplement that has been clinically shown to alleviate arthritis joint pain and stiffness; however the mechanism of action is not well understood. Preliminary evidence from an in vitro study of NEM® indicated that the mechanism of action may be based on the reduction of pro-inflammatory cytokines. In vivo studies were therefore initiated to evaluate the effects of NEM® on pro-inflammatory and anti-inflammatory cytokines following oral administration in rats. NEM® was administered daily at doses of 6.13 mg/kg bw/day (Study 1), 10.0 mg/kg bw/day (Study 2), or at doses of 0 (control), 26.0 or 52.0 mg/kg bw/day (Study 3) by oral gavage for 7 consecutive days. Inflammation was induced in the Study 3 rats by intraperitoneal injection of lipopolysaccharide. Changes in plasma cytokine levels from baseline following 7 days of oral supplementation with NEM® at 6.13 mg/kg bw/ day (Study 1) were statistically significant at Day 8 for IL-2, TIMP-1 and VEGF, at Day 21 for IL-10, and at Day 35 for MCP-1, MCP-3 and TIMP-1, and at 10.0 mg/kg bw/day (Study 2) were statistically significant at Day 8 for VEGF, at Day 21 for MIP-1β, MIP-2 and VEGF, and at Day 35 for MCP-3, MIP-1β, MIP-2 and VEGF. Changes in serum cytokine levels versus control at 26.0 mg/kg bw/day (Study 3) were statistically significant at all time-points for IL-1β and at 1.5 hours for IL-10, and at 52.0 mg/kg bw/day (Study 3) were statistically significant at 1.5 hours for IFN-γ, IL-1β and IL-10, and at 3 hours for IL-1β, and at 24 hours for IL-10. Taken together, these studies demonstrate that oral supplementation with NEM® can influence both early-phase pro-inflammatory cytokines like IL-1β and TNF-α (Study 3), as well as later-phase cytokines like MCP-1, MIP-1α & β, RANTES and VEGF (Study 1 & 2). These studies provide a possible basis for the mechanism of action of NEM® in vivo.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Twitter Digg Delicious Stumbleupon Technorati Facebook Email